Saturday, January 1, 2011

Gilead could change the game for HIV patients

Date: Friday, December 31, 2010, 3:00am PST

Biotech: Pill to watch-Gilead Sciences' Quad pill
 Foster City-based Gilead could change the game for HIV patients and its bottom line, adding a new drug and booster to its once-a-day pill.
The so-called Quad pill and its elements are undergoing three Phase III studies. A fourth 700-patient trial is enrolling.
About half of the HIV patients who start therapy in the United States already use Gilead’s three-in-one Atripla, which uses Bristol-Myers Squibb’s Sustiva. The Quad pill drops the Bristol-Myers Squibb drug and uses Viread, Emtriva and a new Gilead drug called elvitegravir plus an elvitegravir booster.
Wall Street analysts have pegged the pill as a $4 billion-a-year ...


Read more: Biotech: Pill to watch-Gilead Sciences' Quad pill | San Francisco Business Times 

1 comment:

  1. Lindsay Rosenwald http://www.lindsayrosenwald.com/lindsay-rosenwald-director-republican-jewish-coalition/ Lindsay Rosenwald – Director Of Republican Jewish Coalition and his accomplishments in field of Biotechnology.

    ReplyDelete